Non-Syndromic Hearing Loss Panel

SEQmethod-seq-icon Our Sequence Analysis is based on a proprietary targeted sequencing method OS-Seq™ and offers panels targeted for genes associated with certain phenotypes. A standard way to analyze NGS data for finding the genetic cause for Mendelian disorders. Results in 21 days. DEL/DUPmethod-dup-icon Targeted Del/Dup (CNV) analysis is used to detect bigger disease causing deletions or duplications from the disease-associated genes. Results in 21 days. PLUSmethod-plus-icon Plus Analysis combines Sequence + Del/Dup (CNV) Analysis providing increased diagnostic yield in certain clinical conditions, where the underlying genetic defect may be detectable by either of the analysis methods. Results in 21 days.

Test code: EA0201

The Blueprint Genetics Non-Syndromic Hearing Loss Panel is a 93 gene test for genetic diagnostics of patients with clinical suspicion of non-syndromic genetic deafness or sensorineural hearing loss, unilateral and bilateral.

The inheritance of most types of non-syndromic hearing loss is autosomal recessive. However, also autosomal dominant as well as X-linked forms are present. Genes and mutations causative for sensorineural non-syndromic hearing loss are often population-specific and the clinical utility of this Panel varies consequently. In addition to non-syndromic hearing loss, this Panel have differential diagnostics power to some specific syndromes with hearing loss (for example Usher syndrome, Baraitser-Winter syndrome, branchio-oto-renal (BOR) syndrome), but in general, the Syndromic Hearing Loss Panel is recommended for genetic diagnostic of patients with hearing loss interlinked with symptoms affecting other parts of the body. In addition to protein coding regions, two disease causing intronic variants of HGF gene are targeted in this Panel. This Panel is included in the Comprehensive Hearing Loss and Deafness Panel.

About Non-Syndromic Hearing Loss

Sensorineural hearing loss is a genetically very heterogenous group of phenotypes varying in severity and causes. Non-syndromic sensorineural hearing loss is a partial or total loss of hearing that occurs in isolation, without other associated medical disorders. Hearing loss can be unilateral or bilateral and it can be stable or progressive. In addition, specific types of non-syndromic hearing loss may show distinctive pattern of hearing loss for high, middle or low tones. Some 75%-to-85% of congenital hereditary hearing impairnment have non-syndromic origin and the prevalence is estimated to be 3-4:10000 neonates and increases with age. In many populations, mutations in GJB2 are the most prevalent explaining up to 50% of all non-syndromic hearing losses.

Availability

Results in 3-4 weeks.

Genes in the Non-Syndromic Hearing Loss Panel and their clinical significance
GeneAssociated phenotypesInheritanceClinVarHGMD
ACTG1*Deafness, Baraitser-Winter syndromeAD1737
ADCY1DeafnessAR11
BDP1*Hearing lossAD/AR1
BSNDSensorineural deafness with mild renal dysfunction, Bartter syndromeAR1021
CABP2DeafnessAR16
CCDC50DeafnessAD13
CDH23Deafness, Usher syndromeAR/Digenic48294
CEACAM16DeafnessAD33
CIB2Deafness, Usher syndromeAR415
CLDN14DeafnessAR811
CLIC5DeafnessAR11
COCHDeafnessAD1027
COL4A6Deafness, with cochlear malformationXL124
COL11A2Weissenbacher-Zweymuller syndrome, Deafness, Otospondylomegaepiphyseal dysplasia, FibrochondrogenesisAD/AR1751
CRYMDeafnessAD23
DCDC2DeafnessAR411
DFNA5DeafnessAD68
DFNB31Deafness, Usher syndromeAR928
DFNB59DeafnessAR719
DIABLODeafnessAD12
DIAPH1DeafnessAD412
DIAPH3Non-syndromic sensorineural deafnessAD/AR16
DSPPDentin dysplasia, Dentinogenesis imperfecta, Deafness, with dentinogenesis imperfectaAD848
ELMOD3DeafnessAR11
EPS8DeafnessAR12
ESPN*DeafnessAD/AR711
ESRRBDeafnessAR816
EYA4Dilated cardiomyopathy (DCM)AD822
FAM65BDeafnessAR11
GIPC3DeafnessAR917
GJB2Deafness, Bart-Pumphrey syndrome, Keratoderma, palmoplantar, with deafness, Vohwinkel syndrome, Hystrix-like ichthyosis with deafness, Keratitis-icthyosis-deafness syndromeAD/AR/Digenic96385
GJB3DeafnessAD/Digenic837
GJB6DeafnessAR/Digenic828
GPSM2Deafness, Chudley-McCullough syndromeAR1011
GRHL2Ectodermal dysplasia/short stature syndromeAD/AR66
GRXCR1DeafnessAR49
GRXCR2DeafnessAR11
HGFDeafnessAR412
HOMER2DeafnessAD22
ILDR1DeafnessAR422
KARSCharcot-Marie-Tooth diseaseAR614
KCNQ4DeafnessAD2435
LHFPL5DeafnessAR410
LOXHD1DeafnessAR1237
LRTOMTDeafnessAR616
MARVELD2DeafnessAR615
METDeafness, Renal cell carcinoma, papillaryAD/AR1323
MIR96DeafnessAD24
MSRB3DeafnessAR42
MYH9Sebastian syndrome, May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, Macrothrombocytopenia and progressive sensorineural deafnessAD19113
MYH14Deafness, Peripheral neuropathy, myopathy, hoarseness, and hearing lossAD626
MYO1ADeafnessAD116
MYO3ADeafnessAR618
MYO6DeafnessAR1447
MYO7ADeafness, Usher syndromeAR125402
MYO15ADeafnessAR48209
NARS2Combined oxidative phosphorylation deficiencyAR36
OSBPL2DeafnessAD23
OTOA*DeafnessAR1224
OTOFNeuropathy, DeafnessAR94153
OTOGDeafnessAR53
OTOGLDeafnessAR1017
P2RX2DeafnessAD23
PCDH15Deafness, Usher syndromeAR/Digenic2897
PNPT1*DeafnessAR124
POU3F4DeafnessXL1966
POU4F3DeafnessAD614
PRPS1*Deafness, Phosphoribosylpyrophosphate synthetase I superactivity, Arts syndromeXL2226
PTPRQDeafnessAR527
RDX*DeafnessAR57
SERPINB6DeafnessAR13
SIX1Deafness, Branchiootic syndrome, Branchiootorenal syndromeAD915
SLC17A8DeafnessAD15
SLC26A4Deafness, Pendred syndrome, Enlarged vestibular aqueductAR98521
SLC26A5DeafnessAR27
SLITRK6Deafness and myopiaAR33
SMPXDeafnessXL59
STRC*DeafnessAR2471
SYNE4DeafnessAR41
TBC1D24Deafness, Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures (DOORS) syndromeAD/AR2741
TECTADeafnessAD/AR1797
TJP2Cholestasis, progressive familial intrahepatic, Hypercholanemia, familialAR1515
TMC1DeafnessAR2384
TMC2Hearing lossAD/AR
TMEM132EHearing lossAD/AR1
TMIEDeafnessAR810
TMPRSS3DeafnessAR2066
TNCDeafnessAD25
TPRNDeafnessAR510
TRIOBPDeafnessAR1332
TSPEARDeafnessAR18
USH1CDeafness, Usher syndromeAR1345
WFS1Wolfram syndromeAR59343
  • * Some regions of the gene are duplicated in the genome leading to limited sensitivity within the regions. Thus, low-quality variants are filtered out from the duplicated regions and only high-quality variants confirmed by other methods are reported out. Read more.

Gene, refers to HGNC approved gene symbol; Inheritance to inheritance patterns such as autosomal dominant (AD), autosomal recessive (AR) and X-linked (XL); ClinVar, refers to a number of variants in the gene classified as pathogenic or likely pathogenic in ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/); HGMD, refers to a number of variants with possible disease association in the gene listed in Human Gene Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/ac/). The list of associated (gene specific) phenotypes are generated from CDG (http://research.nhgri.nih.gov/CGD/) or Orphanet (http://www.orpha.net/) databases.

Blueprint Genetics offers a comprehensive non-Syndromic hearing loss panel that covers classical genes associated with Baraitser-Winter syndrome, branchio-oto-renal (BOR) syndrome, non-syndromic genetic deafness, sensorineural hearing loss, unilateral and bilateral and Usher syndrome. The genes are carefully selected based on the existing scientific evidence, our experience and most current mutation databases. Candidate genes are excluded from this first-line diagnostic test. The test does not recognise balanced translocations or complex inversions, and it may not detect low-level mosaicism. The test should not be used for analysis of sequence repeats or for diagnosis of disorders caused by mutations in the mitochondrial DNA.

Please see our latest validation report showing sensitivity and specificity for SNPs and indels, sequencing depth, % of the nucleotides reached at least 15x coverage etc. If the Panel is not present in the report, data will be published when the Panel becomes available for ordering. Analytical validation is a continuous process at Blueprint Genetics. Our mission is to improve the quality of the sequencing process and each modification is followed by our standardized validation process. All the Panels available for ordering have sensitivity and specificity higher than > 0.99 to detect single nucleotide polymorphisms and a high sensitivity for indels ranging 1-19 bp. The diagnostic yield varies substantially depending on the used assay, referring healthcare professional, hospital and country. Blueprint Genetics’ Plus Analysis (Seq+Del/Dup) maximizes the chance to find molecular genetic diagnosis for your patient although Sequence Analysis or Del/Dup Analysis may be cost-effective first line test if your patient’s phenotype is suggestive for a specific mutation profile. Detection limit for Del/Dup analysis varies through the genome from one to six exon Del/Dups depending on exon size, sequencing coverage and sequence content.

The sequencing data generated in our laboratory is analyzed with our proprietary data analysis and annotation pipeline, integrating state-of-the art algorithms and industry-standard software solutions. Incorporation of rigorous quality control steps throughout the workflow of the pipeline ensures the consistency, validity and accuracy of results. The highest relevance in the reported variants is achieved through elimination of false positive findings based on variability data for thousands of publicly available human reference sequences and validation against our in-house curated mutation database as well as the most current and relevant human mutation databases. Reference databases currently used are the 1000 Genomes Project (http://www.1000genomes.org), the NHLBI GO Exome Sequencing Project (ESP; http://evs.gs.washington.edu/EVS), the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org), ClinVar database of genotype-phenotype associations (http://www.ncbi.nlm.nih.gov/clinvar) and the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk). The consequence of variants in coding and splice regions are estimated using the following in silico variant prediction tools: SIFT (http://sift.jcvi.org), Polyphen (http://genetics.bwh.harvard.edu/pph2/), and Mutation Taster (http://www.mutationtaster.org).

Through our online ordering and statement reporting system, Nucleus, the customer can access specific details of the analysis of the patient. This includes coverage and quality specifications and other relevant information on the analysis. This represents our mission to build fully transparent diagnostics where the customer gains easy access to crucial details of the analysis process.

In addition to our cutting-edge patented sequencing technology and proprietary bioinformatics pipeline, we also provide the customers with the best-informed clinical report on the market. Clinical interpretation requires fundamental clinical and genetic understanding. At Blueprint Genetics our geneticists and clinicians, who together evaluate the results from the sequence analysis pipeline in the context of phenotype information provided in the requisition form, prepare the clinical statement. Our goal is to provide clinically meaningful statements that are understandable for all medical professionals, even without training in genetics.

Variants reported in the statement are always classified using the Blueprint Genetics Variant Classification Scheme modified from the ACMG guidelines (Richards et al. 2015), which has been developed by evaluating existing literature, databases and with thousands of clinical cases analyzed in our laboratory. Variant classification forms the corner stone of clinical interpretation and following patient management decisions. Our statement also includes allele frequencies in reference populations and in silico predictions. We also provide PubMed IDs to the articles or submission numbers to public databases that have been used in the interpretation of the detected variants. In our conclusion, we summarize all the existing information and provide our rationale for the classification of the variant.

A final component of the analysis is the Sanger confirmation of the variants classified as likely pathogenic or pathogenic. This does not only bring confidence to the results obtained by our NGS solution but establishes the mutation specific test for family members. Sanger sequencing is also used occasionally with other variants reported in the statement. In the case of variant of uncertain significance (VUS) we do not recommend risk stratification based on the genetic finding. Furthermore, in the case VUS we do not recommend use of genetic information in patient management or genetic counseling. For some cases Blueprint Genetics offers a special free of charge service to investigate the role of identified VUS.

We constantly follow genetic literature adapting new relevant information and findings to our diagnostics. Relevant novel discoveries can be rapidly translated and adopted into our diagnostics without delay. These processes ensure that our diagnostic panels and clinical statements remain the most up-to-date on the market.

Find more info in Support
Download PDF

Full service only

Choose an analysis method

$ $ 1700
$ $ 1000
$ $ 1900

Extra services

$ 500
Total $
Order now

ICD & CPT codes

CPT codes

SEQ81430
DEL/DUP81431


ICD codes

Commonly used ICD-10 codes when ordering the Non-Syndromic Hearing Loss Panel

ICD-10Disease
H90.5Sensorineural hearing loss, unilateral and bilateral

Accepted sample types

  • EDTA blood, min. 1 ml
  • Purified DNA, min. 5μg
  • Saliva (Oragene DNA OG-500 kit)

Label the sample tube with your patient’s name, date of birth and the date of sample collection.

Note that we do not accept DNA samples isolated from formalin-fixed paraffin-embedded (FFPE) tissue.